Williams DA (24 January 2012). "Antidepressants". In Lemke TL, Williams DA (eds.). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 591–. ISBN978-1-60913-345-0.
Delini-Stula A, Mikkelsen H, Angst J (October 1995). "Therapeutic efficacy of antidepressants in agitated anxious depression--a meta-analysis of moclobemide studies". Journal of Affective Disorders. 35 (1–2): 21–30. doi:10.1016/0165-0327(95)00034-K. PMID8557884.
Gachoud JP, Dick P, Köhler M (1994). "Comparison of the efficacy and tolerability of moclobemide and maprotiline in depressed patients treated by general practitioners". Clinical Neuropharmacology. 17 (Suppl 1): S29–37. doi:10.1097/00002826-199417001-00005. PMID7954482. S2CID260560762.
Vrethem M, Boivie J, Arnqvist H, Holmgren H, Lindström T, Thorell LH (December 1997). "A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics". The Clinical Journal of Pain. 13 (4): 313–23. doi:10.1097/00002508-199712000-00009. PMID9430812.
Singh R, Kishore L, Kaur N (February 2014). "Diabetic peripheral neuropathy: current perspective and future directions". Pharmacological Research. 80: 21–35. doi:10.1016/j.phrs.2013.12.005. PMID24373831. S2CID6097534.
Cloonan SM, Drozgowska A, Fayne D, Williams DC (March 2010). "The antidepressants maprotiline and fluoxetine have potent selective antiproliferative effects against Burkitt lymphoma independently of the norepinephrine and serotonin transporters". Leukemia & Lymphoma. 51 (3): 523–39. doi:10.3109/10428190903552112. PMID20141432. S2CID33104465.
Cloonan SM, Williams DC (April 2011). "The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug-resistant Burkitt's lymphoma". International Journal of Cancer. 128 (7): 1712–23. doi:10.1002/ijc.25477. PMID20503272. S2CID24955263.
Sufka KJ, White SW (November 2013). "Identification of a treatment-resistant, ketamine-sensitive genetic line in the chick anxiety-depression model". Pharmacology, Biochemistry, and Behavior. 113: 63–7. doi:10.1016/j.pbb.2013.10.013. PMID24157688. S2CID23648185.
Berger M, Gastpar M (1996). "Trimipramine: a challenge to current concepts on antidepressives". European Archives of Psychiatry and Clinical Neuroscience. 246 (5): 235–9. doi:10.1007/BF02190274. PMID8863001. S2CID29596291.
Eikmeier G, Muszynski K, Berger M, Gastpar M (September 1990). "High-dose trimipramine in acute schizophrenia. Preliminary results of an open trial". Pharmacopsychiatry. 23 (5): 212–4. doi:10.1055/s-2007-1014510. PMID1979173. S2CID5719177.
Eikmeier G, Berger M, Lodemann E, Muszynski K, Kaumeier S, Gastpar M (1991). "Trimipramine--an atypical neuroleptic?". International Clinical Psychopharmacology. 6 (3): 147–53. doi:10.1097/00004850-199100630-00003. PMID1806621. S2CID41564511.
Waehrens J, Gerlach J (May 1980). "Antidepressant drugs in anergic schizophrenia. A double-blind cross-over study with maprotiline and placebo". Acta Psychiatrica Scandinavica. 61 (5): 438–44. doi:10.1111/j.1600-0447.1980.tb00882.x. PMID6105762. S2CID40809634.
Silver H, Shmugliakov N (June 1998). "Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study". Journal of Clinical Psychopharmacology. 18 (3): 208–11. doi:10.1097/00004714-199806000-00005. PMID9617979.
Wehr TA, Goodwin FK (November 1987). "Can antidepressants cause mania and worsen the course of affective illness?". The American Journal of Psychiatry. 144 (11): 1403–11. doi:10.1176/ajp.144.11.1403. PMID3314536.
Azorin JM, Belzeaux R, Cermolacce M, Kaladjian A, Corréard N, Dassa D, Dubois M, Maurel M, Micoulaud Franchi JA, Pringuey D, Fakra E (December 2013). "[Recommendations for the treatment of mixed episodes in current guidelines]". L'Encephale (in French). 39 (Suppl 3): S185–7. doi:10.1016/S0013-7006(13)70120-9. PMID24359859.
Hoencamp E, Haffmans PM, Dijken WA, Hoogduin CA, Nolen WA, van Dyck R (March 1994). "Brofaromine versus lithium addition to maprotiline. A double-blind study in maprotiline refractory depressed outpatients". Journal of Affective Disorders. 30 (3): 219–27. doi:10.1016/0165-0327(94)90082-5. PMID8006248.
König F, Wolfersdorf M, Löble M, Wössner S, Hauger B (July 1997). "Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy-resistant depression". Pharmacopsychiatry. 30 (4): 125–7. doi:10.1055/s-2007-979497. PMID9271778. S2CID35570626.
Tatsumi M, Groshan K, Blakely RD, Richelson E (December 1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". European Journal of Pharmacology. 340 (2–3): 249–258. doi:10.1016/s0014-2999(97)01393-9. PMID9537821.
Heffernan GD, Coghlan RD, Manas ES, McDevitt RE, Li Y, Mahaney PE, et al. (November 2009). "Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles". Bioorganic & Medicinal Chemistry. 17 (22): 7802–7815. doi:10.1016/j.bmc.2009.09.023. PMID19836247.
Pälvimäki EP, Roth BL, Majasuo H, Laakso A, Kuoppamäki M, Syvälahti E, Hietala J (August 1996). "Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor". Psychopharmacology. 126 (3): 234–240. doi:10.1007/bf02246453. PMID8876023. S2CID24889381.
Lucchelli A, Santagostino-Barbone MG, D'Agostino G, Masoero E, Tonini M (September 2000). "The interaction of antidepressant drugs with enteric 5-HT7 receptors". Naunyn-Schmiedeberg's Archives of Pharmacology. 362 (3): 284–289. doi:10.1007/s002100000295. PMID10997731. S2CID24189673.
von Coburg Y, Kottke T, Weizel L, Ligneau X, Stark H (January 2009). "Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics". Bioorganic & Medicinal Chemistry Letters. 19 (2): 538–542. doi:10.1016/j.bmcl.2008.09.012. PMID19091563.
Appl H, Holzammer T, Dove S, Haen E, Strasser A, Seifert R (February 2012). "Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics". Naunyn-Schmiedeberg's Archives of Pharmacology. 385 (2): 145–170. doi:10.1007/s00210-011-0704-0. PMID22033803. S2CID14274150.
Peng WH, Lo KL, Lee YH, Hung TH, Lin YC (August 2007). "Berberine produces antidepressant-like effects in the forced swim test and in the tail suspension test in mice". Life Sciences. 81 (11): 933–938. doi:10.1016/j.lfs.2007.08.003. PMID17804020.
Matthys A, Haegeman G, Van Craenenbroeck K, Vanhoenacker P (June 2011). "Role of the 5-HT7 receptor in the central nervous system: from current status to future perspectives". Molecular Neurobiology. 43 (3): 228–253. doi:10.1007/s12035-011-8175-3. PMID21424680. S2CID25515856.
Miyake K, Fukuchi H, Kitaura T, Kimura M, Kimura Y, Nakahara T (December 1991). "Pharmacokinetics of maprotiline and its demethylated metabolite in serum and specific brain regions of rats after acute and chronic administration of maprotiline". Journal of Pharmaceutical Sciences. 80 (12): 1114–8. doi:10.1002/jps.2600801205. PMID1815068.
Andersen J, Kristensen AS, Bang-Andersen B, Strømgaard K (July 2009). "Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters". Chemical Communications (25): 3677–3692. doi:10.1039/b903035m. PMID19557250.
Pecknold JC, Familamiri P, McClure DJ, Elie R, Chang H (May 1985). "Trimipramine and maprotiline: antidepressant, anxiolytic, and cardiotoxic comparison". The Journal of Clinical Psychiatry. 46 (5): 166–171. PMID2859273.
Brownell LG, Perez-Padilla R, West P, Kryger MH (1983). "The role of protriptyline in obstructive sleep apnea". Bulletin Européen de Physiopathologie Respiratoire. 19 (6): 621–4. PMID6360257.
Delini-Stula A, Mikkelsen H, Angst J (October 1995). "Therapeutic efficacy of antidepressants in agitated anxious depression--a meta-analysis of moclobemide studies". Journal of Affective Disorders. 35 (1–2): 21–30. doi:10.1016/0165-0327(95)00034-K. PMID8557884.
Gachoud JP, Dick P, Köhler M (1994). "Comparison of the efficacy and tolerability of moclobemide and maprotiline in depressed patients treated by general practitioners". Clinical Neuropharmacology. 17 (Suppl 1): S29–37. doi:10.1097/00002826-199417001-00005. PMID7954482. S2CID260560762.
Vrethem M, Boivie J, Arnqvist H, Holmgren H, Lindström T, Thorell LH (December 1997). "A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics". The Clinical Journal of Pain. 13 (4): 313–23. doi:10.1097/00002508-199712000-00009. PMID9430812.
Singh R, Kishore L, Kaur N (February 2014). "Diabetic peripheral neuropathy: current perspective and future directions". Pharmacological Research. 80: 21–35. doi:10.1016/j.phrs.2013.12.005. PMID24373831. S2CID6097534.
Cloonan SM, Drozgowska A, Fayne D, Williams DC (March 2010). "The antidepressants maprotiline and fluoxetine have potent selective antiproliferative effects against Burkitt lymphoma independently of the norepinephrine and serotonin transporters". Leukemia & Lymphoma. 51 (3): 523–39. doi:10.3109/10428190903552112. PMID20141432. S2CID33104465.
Cloonan SM, Williams DC (April 2011). "The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug-resistant Burkitt's lymphoma". International Journal of Cancer. 128 (7): 1712–23. doi:10.1002/ijc.25477. PMID20503272. S2CID24955263.
Sufka KJ, White SW (November 2013). "Identification of a treatment-resistant, ketamine-sensitive genetic line in the chick anxiety-depression model". Pharmacology, Biochemistry, and Behavior. 113: 63–7. doi:10.1016/j.pbb.2013.10.013. PMID24157688. S2CID23648185.
Berger M, Gastpar M (1996). "Trimipramine: a challenge to current concepts on antidepressives". European Archives of Psychiatry and Clinical Neuroscience. 246 (5): 235–9. doi:10.1007/BF02190274. PMID8863001. S2CID29596291.
Eikmeier G, Muszynski K, Berger M, Gastpar M (September 1990). "High-dose trimipramine in acute schizophrenia. Preliminary results of an open trial". Pharmacopsychiatry. 23 (5): 212–4. doi:10.1055/s-2007-1014510. PMID1979173. S2CID5719177.
Eikmeier G, Berger M, Lodemann E, Muszynski K, Kaumeier S, Gastpar M (1991). "Trimipramine--an atypical neuroleptic?". International Clinical Psychopharmacology. 6 (3): 147–53. doi:10.1097/00004850-199100630-00003. PMID1806621. S2CID41564511.
Yamagami S, Soejima K (1989). "Effect of maprotiline combined with conventional neuroleptics against negative symptoms of chronic schizophrenia". Drugs Under Experimental and Clinical Research. 15 (4): 171–6. PMID2570687.
Waehrens J, Gerlach J (May 1980). "Antidepressant drugs in anergic schizophrenia. A double-blind cross-over study with maprotiline and placebo". Acta Psychiatrica Scandinavica. 61 (5): 438–44. doi:10.1111/j.1600-0447.1980.tb00882.x. PMID6105762. S2CID40809634.
Silver H, Shmugliakov N (June 1998). "Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study". Journal of Clinical Psychopharmacology. 18 (3): 208–11. doi:10.1097/00004714-199806000-00005. PMID9617979.
Wehr TA, Goodwin FK (November 1987). "Can antidepressants cause mania and worsen the course of affective illness?". The American Journal of Psychiatry. 144 (11): 1403–11. doi:10.1176/ajp.144.11.1403. PMID3314536.
Kuzman MR, Medved V, Velagic V, Goluza E, Bradas Z (June 2012). "The use of electroconvulsive therapy to treat schizoaffective disorder in a patient with pacemaker: a case report". Psychiatria Danubina. 24 (2): 211–4. PMID22706421.
Azorin JM, Belzeaux R, Cermolacce M, Kaladjian A, Corréard N, Dassa D, Dubois M, Maurel M, Micoulaud Franchi JA, Pringuey D, Fakra E (December 2013). "[Recommendations for the treatment of mixed episodes in current guidelines]". L'Encephale (in French). 39 (Suppl 3): S185–7. doi:10.1016/S0013-7006(13)70120-9. PMID24359859.
Saito S, Kobayashi T, Kato S (2013). "[A case of major depressive disorder barely distinguishable from narcissistic personality disorder]". Seishin Shinkeigaku Zasshi = Psychiatria et Neurologia Japonica (in Japanese). 115 (4): 363–71. PMID23789317.
Laux G, Beckmann H, Classen W, Becker T (1989). "Moclobemide and maprotiline in the treatment of inpatients with major depressive disorder". Journal of Neural Transmission. Supplementum. 28: 45–52. PMID2677241.
Hoencamp E, Haffmans PM, Dijken WA, Hoogduin CA, Nolen WA, van Dyck R (March 1994). "Brofaromine versus lithium addition to maprotiline. A double-blind study in maprotiline refractory depressed outpatients". Journal of Affective Disorders. 30 (3): 219–27. doi:10.1016/0165-0327(94)90082-5. PMID8006248.
König F, Wolfersdorf M, Löble M, Wössner S, Hauger B (July 1997). "Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy-resistant depression". Pharmacopsychiatry. 30 (4): 125–7. doi:10.1055/s-2007-979497. PMID9271778. S2CID35570626.
Tatsumi M, Groshan K, Blakely RD, Richelson E (December 1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". European Journal of Pharmacology. 340 (2–3): 249–258. doi:10.1016/s0014-2999(97)01393-9. PMID9537821.
Heffernan GD, Coghlan RD, Manas ES, McDevitt RE, Li Y, Mahaney PE, et al. (November 2009). "Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles". Bioorganic & Medicinal Chemistry. 17 (22): 7802–7815. doi:10.1016/j.bmc.2009.09.023. PMID19836247.
Pälvimäki EP, Roth BL, Majasuo H, Laakso A, Kuoppamäki M, Syvälahti E, Hietala J (August 1996). "Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor". Psychopharmacology. 126 (3): 234–240. doi:10.1007/bf02246453. PMID8876023. S2CID24889381.
Lucchelli A, Santagostino-Barbone MG, D'Agostino G, Masoero E, Tonini M (September 2000). "The interaction of antidepressant drugs with enteric 5-HT7 receptors". Naunyn-Schmiedeberg's Archives of Pharmacology. 362 (3): 284–289. doi:10.1007/s002100000295. PMID10997731. S2CID24189673.
Richelson E, Nelson A (July 1984). "Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro". The Journal of Pharmacology and Experimental Therapeutics. 230 (1): 94–102. PMID6086881.
von Coburg Y, Kottke T, Weizel L, Ligneau X, Stark H (January 2009). "Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics". Bioorganic & Medicinal Chemistry Letters. 19 (2): 538–542. doi:10.1016/j.bmcl.2008.09.012. PMID19091563.
Appl H, Holzammer T, Dove S, Haen E, Strasser A, Seifert R (February 2012). "Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics". Naunyn-Schmiedeberg's Archives of Pharmacology. 385 (2): 145–170. doi:10.1007/s00210-011-0704-0. PMID22033803. S2CID14274150.
Peng WH, Lo KL, Lee YH, Hung TH, Lin YC (August 2007). "Berberine produces antidepressant-like effects in the forced swim test and in the tail suspension test in mice". Life Sciences. 81 (11): 933–938. doi:10.1016/j.lfs.2007.08.003. PMID17804020.
Matthys A, Haegeman G, Van Craenenbroeck K, Vanhoenacker P (June 2011). "Role of the 5-HT7 receptor in the central nervous system: from current status to future perspectives". Molecular Neurobiology. 43 (3): 228–253. doi:10.1007/s12035-011-8175-3. PMID21424680. S2CID25515856.
Miyake K, Fukuchi H, Kitaura T, Kimura M, Kimura Y, Nakahara T (December 1991). "Pharmacokinetics of maprotiline and its demethylated metabolite in serum and specific brain regions of rats after acute and chronic administration of maprotiline". Journal of Pharmaceutical Sciences. 80 (12): 1114–8. doi:10.1002/jps.2600801205. PMID1815068.
Andersen J, Kristensen AS, Bang-Andersen B, Strømgaard K (July 2009). "Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters". Chemical Communications (25): 3677–3692. doi:10.1039/b903035m. PMID19557250.
Gachoud JP, Dick P, Köhler M (1994). "Comparison of the efficacy and tolerability of moclobemide and maprotiline in depressed patients treated by general practitioners". Clinical Neuropharmacology. 17 (Suppl 1): S29–37. doi:10.1097/00002826-199417001-00005. PMID7954482. S2CID260560762.
Singh R, Kishore L, Kaur N (February 2014). "Diabetic peripheral neuropathy: current perspective and future directions". Pharmacological Research. 80: 21–35. doi:10.1016/j.phrs.2013.12.005. PMID24373831. S2CID6097534.
Cloonan SM, Drozgowska A, Fayne D, Williams DC (March 2010). "The antidepressants maprotiline and fluoxetine have potent selective antiproliferative effects against Burkitt lymphoma independently of the norepinephrine and serotonin transporters". Leukemia & Lymphoma. 51 (3): 523–39. doi:10.3109/10428190903552112. PMID20141432. S2CID33104465.
Cloonan SM, Williams DC (April 2011). "The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug-resistant Burkitt's lymphoma". International Journal of Cancer. 128 (7): 1712–23. doi:10.1002/ijc.25477. PMID20503272. S2CID24955263.
Sufka KJ, White SW (November 2013). "Identification of a treatment-resistant, ketamine-sensitive genetic line in the chick anxiety-depression model". Pharmacology, Biochemistry, and Behavior. 113: 63–7. doi:10.1016/j.pbb.2013.10.013. PMID24157688. S2CID23648185.
Berger M, Gastpar M (1996). "Trimipramine: a challenge to current concepts on antidepressives". European Archives of Psychiatry and Clinical Neuroscience. 246 (5): 235–9. doi:10.1007/BF02190274. PMID8863001. S2CID29596291.
Eikmeier G, Muszynski K, Berger M, Gastpar M (September 1990). "High-dose trimipramine in acute schizophrenia. Preliminary results of an open trial". Pharmacopsychiatry. 23 (5): 212–4. doi:10.1055/s-2007-1014510. PMID1979173. S2CID5719177.
Eikmeier G, Berger M, Lodemann E, Muszynski K, Kaumeier S, Gastpar M (1991). "Trimipramine--an atypical neuroleptic?". International Clinical Psychopharmacology. 6 (3): 147–53. doi:10.1097/00004850-199100630-00003. PMID1806621. S2CID41564511.
Waehrens J, Gerlach J (May 1980). "Antidepressant drugs in anergic schizophrenia. A double-blind cross-over study with maprotiline and placebo". Acta Psychiatrica Scandinavica. 61 (5): 438–44. doi:10.1111/j.1600-0447.1980.tb00882.x. PMID6105762. S2CID40809634.
König F, Wolfersdorf M, Löble M, Wössner S, Hauger B (July 1997). "Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy-resistant depression". Pharmacopsychiatry. 30 (4): 125–7. doi:10.1055/s-2007-979497. PMID9271778. S2CID35570626.
Pälvimäki EP, Roth BL, Majasuo H, Laakso A, Kuoppamäki M, Syvälahti E, Hietala J (August 1996). "Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor". Psychopharmacology. 126 (3): 234–240. doi:10.1007/bf02246453. PMID8876023. S2CID24889381.
Lucchelli A, Santagostino-Barbone MG, D'Agostino G, Masoero E, Tonini M (September 2000). "The interaction of antidepressant drugs with enteric 5-HT7 receptors". Naunyn-Schmiedeberg's Archives of Pharmacology. 362 (3): 284–289. doi:10.1007/s002100000295. PMID10997731. S2CID24189673.
Appl H, Holzammer T, Dove S, Haen E, Strasser A, Seifert R (February 2012). "Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics". Naunyn-Schmiedeberg's Archives of Pharmacology. 385 (2): 145–170. doi:10.1007/s00210-011-0704-0. PMID22033803. S2CID14274150.
Matthys A, Haegeman G, Van Craenenbroeck K, Vanhoenacker P (June 2011). "Role of the 5-HT7 receptor in the central nervous system: from current status to future perspectives". Molecular Neurobiology. 43 (3): 228–253. doi:10.1007/s12035-011-8175-3. PMID21424680. S2CID25515856.
unc.edu
pdsp.unc.edu
Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 7 May 2022.
